SESema Sırma Ekmekci

Sema Sırma Ekmekci

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sema Sırma Ekmekci has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • SPINK2 knockdown reduces proliferation and promotes cell death in MLL–MLLT3-rearranged THP-1 cells

    by Berk İlEri, Sümbül Gezer, Tuğba Kotil, Şeyma Punar, Zeliha Emrence, Neslihan Abacı, Sema Sırma Ekmekci

  • EVALUATION OF SELECTED MICRORNA EXPRESSION PROFILES IN BORTEZOMIBRESISTANT MULTIPLE MYELOMA CELLS

    by Zeliha Emrence, Şeyma Punar, Merve Keskin, Berra Sümer, Büşra Karaçam, Neslihan Abacı, Sema Sırma Ekmekci

    Amaç: Bortezomib, multipl miyelom tedavisinde yaygın olarak kullanılan önemli bir proteazom inhibitörüdür; ancak kazanılmış direnç, ilacın uzun dönem klinik etkinliğini sınırlandırmaktadır. MikroRNA’lar apoptoz, stres yanıtı, hücresel adaptasyon ve ilaç direnci süreçlerinde rol oynayan önemli post-transkripsiyonel düzenleyicilerdir. Bu çalışmada, multipl miyelom hücre modellerinde bortezomib direnci ile ilişkili olabilecek seçilmiş mikroRNA’ların ekspresyon profillerinin araştırılması amaçlandı. Yöntem: Bortezomib dirençli U266 ve RPMI-8226 multipl miyelom hücreleri, artan konsantrasyonlarda bortezomibe sürekli maruz bırakılarak oluşturuldu. Dirençli ve kontrol hücrelerinde miR-25, miR-30c, miR-34a, miR-34c, miR-200b, miR-200c, miR-326, miR-429, miR-449a, miR-449b, miR-499a, miR-582 ve miR-708 ekspresyon düzeyleri kantitatif gerçek zamanlı PCR yöntemi ile analiz edildi. Endojen kontrol olarak U6 snRNA kullanıldı ve relatif ekspresyon düzeyleri 2⁻ΔΔCt yöntemi ile hesaplandı. Bulgular: Bortezomib dirençli U266 ve RPMI-8226 hücrelerinde hem ortak hem de hücre hattına özgü mikroRNA ekspresyon değişiklikleri gözlendi. miR-34a, miR-34c, miR-326, miR-429, miR-449a ve miR-449b her iki dirençli hücre hattında da anlamlı olarak yüksek eksprese edildi. miR-25, miR-200c ve miR-708 ekspresyonları yalnızca dirençli RPMI-8226 hücrelerinde arttı. Buna karşılık, miR-200b, miR-499a ve miR-582 iki dirençli model arasında zıt ekspresyon paternleri sergilerken, miR-30c ekspresyonunda değişiklik saptanmadı. Sonuç: Multipl miyelomda kazanılmış bortezomib direnci, hem ortak hem de hücre hattına özgü mikroRNA değişiklikleri ile ilişkilidir. miR-34, miR-326 ve miR-449 aile üyelerinin her iki dirençli hücre hattında tutarlı şekilde artmış olması, bu mikroRNA’ların proteazom inhibisyonuna karşı gelişen adaptif yanıtlarda rol oynayabileceğini düşündürmektedir. Diğer mikroRNA’larda gözlenen farklı ekspresyon paternleri ise direnç mekanizmalarının heterojen yapısına işaret etmektedir. Bu mikroRNA’ların bortezomib direncindeki fonksiyonel rollerinin aydınlatılması için ileri çalışmalara ihtiyaç vardır.

  • DHRS2 regulates epithelial-mesenchymal transition in breast cancer cells

    by Hümeyra Karaca, Burcu Salman Yaylaz, Vahideh Zarerajabi, Şeyma Punar, Sema Sirma Ekmekci, Neslihan Abaci

  • Investigation of advanced glycosylation end products, NF-κB activation, Nrf-2 rs35652124, rs6721961 regions on endoplasmic reticulum stress in peripheral artery disease

    by Hatice Zühre Kara, Fatih Yanar, Şeyma Punar, Neslihan Abacı, Sema Sırma Ekmekçi, Yılmaz Başar, Nihal Salmayenli, Elif Özkök

    Purpose Oxidative stress and inflammation, and the accumulation of unfolded proteins are primary causes in the pathophysiology of peripheral artery disease (PAD), which develops in the presence of type 2 diabetes mellitus (T2DM), characterized by hyperglycemia and insulin resistance. It has been reported that the interaction between endoplasmic reticulum (ER) stress protein, protein disulfide isomerase (PDIA4), and receptor for advanced glycation end products (RAGE) make significant contributions to these processes. Our study aimed to investigate variations in the Nrf-2 rs35652124 and Nrf-2 rs6721961 polymorphic regions in PAD and examine the relationship between these variations and RAGE and PDIA4 protein levels. Methods The study included 114 patients aged 50–75 years with PAD from the Peripheral Vascular Surgery Outpatient Clinic of the General Surgery Department, Istanbul University Faculty of Medicine, and 50 healthy adults as a control group. RAGE and PDIA4 were examined using enzyme-linked immunosorbent assay. Nrf-2 rs35652124, rs6721961 were studied using restriction fragment length polymorphism (RFLP) following polymerase chain reaction in DNA. Results PDIA4 and RAGE were found to be highly significant (p < 0.001, for both) in PAD. PDIA4 (p = 0.002) and RAGE (p = 0.001) were found to be higher in Nrf-2 rs6721961 (-617 G/T) GG and Nrf-2 rs35652124 (-653 T/C) TT in PAD. In the receiver operating characteristic (ROC) analysis performed for PDIA4 and RAGE, significant values were obtained (p < 0.001, for both). Conclusion PDIA4 and RAGE levels were found to be significantly increased in the PAD group. PDIA4 and RAGE were found to be significantly higher in patients with Nrf-2 6,721,961 G and T alleles in the PAD group. PDIA4 and RAGE were significantly higher in those with Nrf-2 rs35652124 T allele in the PAD group. It was found that diabetes might influence the Nrf-2 rs35652124 C allele in the PAD group. ROC analysis revealed that serum PDIA4 and RAGE proteins may have high sensitivity and specificity values in PAD.

  • Open Access

    miR-30c-2-3p Regulates METTL14 Expression and Inhibits Cell Migration in Breast Cancer

    by Zeliha Emrence, Seyma Punar, Vahideh Zarerajabi, Sena Uslu, Neslihan Abaci, Sema Sirma Ekmekci

    Breast cancer remains a leading cause of cancer-related mortality worldwide, with epigenetic mechanisms like N6 methyladenosine (m6A) modification playing a crucial role in tumorigenesis. The interaction between microRNAs and m6A regulators, such as the methyltransferase METTL14, is increasingly recognized as a key pathway in oncogenesis. This study investigated whether miR-30c-2-3p regulates METTL14 expression to influence global m6A levels and cell migration in breast epithelial (MCF12A) and breast cancer (MCF7) cell lines. Following transfection with miR-30c-2-3p mimics, successful overexpression was confirmed in both cell lines. Subsequent RT-qPCR and Western blotting analyses demonstrated that METTL14 mRNA and protein levels were significantly reduced at 24 and 48 h post-transfection (p < 0.05). Concurrently, global m6A RNA methylation levels decreased, with a more pronounced reduction observed in MCF12A cells (p < 0.001). Functionally, wound healing assays revealed that miR-30c-2-3p significantly inhibited migration, reducing wound closure by 30–44% in MCF7 cells and by 66–72% in MCF12A cells. These findings reveal a novel regulatory axis involving miR-30c-2-3p, METTL14, and m6A, suggesting that miR-30c-2-3p functions as a tumor suppressor and represents a promising biomarker and therapeutic target in breast cancer.

  • EVALUATION OF GENETIC TESTING IN ADULT PATIENTS WITH SUSPECTED SYSTEMIC AUTOINFLAMMATORY DISORDERS

    by Shirkhan Amikishiyev, Yıldız Akbal Engin, Tuğba Kalaycı, Lala Soltanova, Yasemin Yalçınkaya, Bahar Artım Esen, Murat İnAnç, Ayla Şahin, Aynur Aday, Sema Ekmekçi, et al.

    Objective: This study aimed to compare the clinical features of patients with suspected systemic autoinflammatory diseases (SAIDs) by genetic status to identify the characteristics of variant-negative patients.Materials and Methods: Clinical findings and results of the targeted next-generation sequencing of “fever panel genes” of patients with suspected SAIDs were retrospectively reviewed using their medical records.Results: Records of 137 patients (79 females, 58 males, mean age 40.8±12.6) referred to our clinic between April 2019 and January 2023 were evaluated. Variants associated with the relevant phenotypes were identified in 105 patients (76.6%), whereas 32 (23.4%) had no pathogenic or likely pathogenic variants, nor variants of uncertain significance (VUS). Variant-negative patients were older at diagnosis than variant-positive ones (38.2±13.6 vs. 28.4±14.8 years; p=0.02). Fever and arthritis occurred with a similar frequency between the groups. Compared with the variant-positive patients, the variant-negative group more often presented with nausea, weight loss, diarrhoea, erythema nodosum, headache, and sensorineural hearing loss (SNHL). Cerebrovascular occlusion occurred more frequently among variant-positive patients.Conclusion: Our study illustrates that the yield of genetic screening is expected to be low in patients older than 40 years and those presenting with nausea, weight loss, diarrhoea, erythema nodosum, headache, and SNHL. A better definition of those variant-negative patients may identify some subgroups of patients with SAID features associated with potential multifactorial causes or somatic mosaic variants.

    • 3 October 2025
      • Vol. 20  (4) , 413-421

    EFFECTS OF VARIATIONS IN BONE METABOLISM RELATED GENES ON BONE MINERAL DENSITY OF PATIENTS WITH OSTEOPOROSIS

    by A.M. Güler, Z. Emrence, E.N. Bozdağ, F. Paçal, N. Abacı, R. Tanakol, S.S. Ekmekci

    Osteoporosis is a complex disease and its development is influenced by genetic, epigenetic, metabolic, and environmental factors. However, specific genetic factors associated with osteoporosis are not fully understood. The aim of this study was to identify genetic risk factors for osteoporosis. This study included 86 females with osteoporosis and 47 healthy females. We analyzed rs1800587, rs16944, rs1799814, rs4988321, rs2228570, and rs35211496 variations in IL1A, IL1B, CYP1A1, LRP5, VDR, and RANK, respectively, using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Our analysis revealed that the CT and TT genotype for rs1800587 in IL1A was associated with higher bone mineral density in the lumbar spine, trochanter, Ward's triangle, and femoral neck (p=0.020, p=0.021, p=0.015, and p=0.013, respectively). The rs1800587 variation in IL1A was associated with a reduced risk of osteoporosis in both dominant and codominant inheritance models (CC vs. CT, p=0.016 and CC vs. CT/TT, p=0.035, respectively). However, we did not identify any statistically significant differences in either genotype or allele frequencies between the control group and the patients with osteoporosis for the other genetic variations examined. Our findings suggest that the rs1800587 variation in IL1A gene is associated with a significantly decreased risk of osteoporosis in the Turkish population.

  • Integrated stress response in Behçet disease: expression analyses in peripheral blood and synovial monocytes

    by İrem Coşkuntan, Ferda Paçal, Fulya Coşan, Esin Çetin Aktaş, Günnur Deniz, Duran Üstek, Sema Sırma Ekmekci, Neslihan Abacı, Ahmet Gül

    Behçet disease (BD) is a chronic, relapsing inflammatory disorder, and human leukocyte antigen (HLA)-B*51 is considered to be the strongest genetic susceptibility factor. The integrated stress response (ISR), defined by the eIF2α/ATF4 axis, is a signaling network that maintains protein homeostasis and regulates innate immunity in eukaryotic cells; pathological activation of this pathway can affect the immune response and cause various diseases. In this study, we aimed to investigate the role of the ISR signaling pathway in the pathogenesis of BD. The study group comprised 83 BD patients and 33 matched healthy controls. eIF2α, PERK, HRI, HSPB8, and ATF4 mRNA expression analysis was performed by real-time quantitative polymerase chain reaction (RTq-PCR) using cDNA prepared from monocytes isolated from peripheral blood and synovial fluid. HLA-B*51 status was available for 73 BD patients. ISR analysis revealed decreased expression of eIF2α and increased expression of PERK, HRI, HSPB8, and ATF4 genes in BD compared to controls (all p < 0.05). Findings of synovial fluid monocytes of active BD patients with arthritis showed a consistent (p = 0.0417, one-tailed) increase in HSPB8 expression and strong correlation with those in corresponding blood monocytes. BD patients exhibit dysregulated ISR signatures regardless of HLA-B*51 status. Despite limitations in sample size and in vivo validation, our findings implicate these signaling pathways as potential contributors to the pathogenesis of BD and possibly other the major histocompatibility complex (MHC) class I-associated diseases.

  • Open Access

    Comment on: NETs in the spotlight: exploring NETosis markers for tracking disease activity in IgA vasculitis: Reply

    by Vafa Guliyeva, Fatma Gül Demirkan, Erdem Bektaş, Rabia Deniz, Zeliha Emrence, Özlem Akgün, Selen Duygu Arık, Ayşenur Doğru, Ayşe Tanatar, Neslihan Abacı, et al.